NewTimeSpace News, as of 10:25 on March 10, 2026, Innovative Medicine ETF (E Fund) (516080) rose 2.56%, with the latest price at 0.64 yuan. Looking at a longer time frame, as of March 9, 2026, Innovative Medicine ETF (E Fund) has cumulatively gained 11.83% over the past year, ranking 1st among 7 comparable funds in terms of gains. (The stocks listed above are index constituents only and do not represent specific recommendations.)

In terms of liquidity, Innovative Medicine ETF (E Fund) recorded a turnover rate of 0.99% intraday, with trading volume reaching 11.9201 million yuan. Looking at a longer time frame, as of March 9, the average daily trading volume over the past week was 25.4756 million yuan, ranking among the top 3 comparable funds.

In terms of scale, Innovative Medicine ETF (E Fund) has grown by 21.6231 million yuan over the past week, achieving significant growth and ranking 3rd among 7 comparable funds in terms of new scale additions. (Data Source: Wind)

In terms of shares, Innovative Medicine ETF (E Fund) has reached 1.883 billion shares most recently, hitting a new high for the past year and ranking 3rd among 7 comparable funds. (Data Source: Wind)

Regarding capital inflows, Innovative Medicine ETF (E Fund) recorded a net capital inflow of 9.3224 million yuan most recently. Looking at a longer time frame, there were net capital inflows on 8 out of the past 10 trading days, totaling 29.5767 million yuan in "capital attraction," with an average daily net inflow of 2.9577 million yuan. (Data Source: Wind)

Data shows that leveraged funds continue to build positions. Innovative Medicine ETF (E Fund) recorded a latest margin purchase amount of 1.3827 million yuan, with the latest financing balance reaching 21.4719 million yuan. (Data Source: Wind)

As of March 9, Innovative Medicine ETF (E Fund) has risen 17.98% in net asset value over the past 2 years, ranking first among comparable funds. In terms of return capability, as of March 9, 2026, since its inception, Innovative Medicine ETF (E Fund) has achieved a maximum monthly return of 22.96%, a longest consecutive rising streak of 5 months, a maximum consecutive gain of 33.43%, and an average return of 5.75% during rising months. As of March 9, 2026, the annualized excess return over the benchmark since inception is 3.14%.

In terms of drawdown, as of March 9, 2026, the relative benchmark drawdown of Innovative Medicine ETF (E Fund) year-to-date is 0.02%, representing the smallest drawdown among comparable funds.

In terms of fees, Innovative Medicine ETF (E Fund) has a management fee of 0.15% and a custody fee of 0.05%, representing the lowest fee structure among comparable funds.

From a valuation perspective, the CSI Innovative Medicine Industry Index tracked by Innovative Medicine ETF (E Fund) has a latest price-to-earnings ratio (PE-TTM) of only 47.14x, at the 11.41st percentile over the past year, meaning the valuation is lower than 88.59% of the time over the past year, placing it at a historical low.

Innovative Medicine ETF (E Fund) closely tracks the CSI Innovative Medicine Industry Index. The CSI Innovative Medicine Industry Index selects up to 50 most representative securities from listed companies whose main business involves innovative drug research and development as index samples, aiming to reflect the overall performance of securities of listed companies in the innovative medicine industry.

On the news front, as commercialization capabilities improve, innovative drug companies are approaching a critical inflection point of turning losses into profits. Based on disclosed 2025 preliminary earnings data, many companies achieved net profit growth or reduced losses in 2025.

Guosheng Securities stated that for the pharmaceutical sector, the positioning of biopharmaceuticals in policy is being further upgraded from "emerging track cultivation" to "an important pillar direction for economic growth and industrial upgrading," with innovative drugs, as the most core high-value-added segment of the biopharmaceutical industry, being particularly clear beneficiaries.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.